COVID Monitor

Friday, November 25, 2022
Data as of November 24, 2022

Cumulative New Cases and Deaths

<table>
<thead>
<tr>
<th>Worldwide</th>
<th>ASEAN+3</th>
<th>Plus-3</th>
<th>ASEAN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>640,360,237 Cases</td>
<td>88,616,120 Cases</td>
<td>53,356,960 Cases</td>
<td>35,259,164 Cases</td>
</tr>
<tr>
<td>6,627,833 Deaths</td>
<td>453,100 Deaths</td>
<td>94,937 Deaths</td>
<td>358,163 Deaths</td>
</tr>
</tbody>
</table>

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.

Recent Developments

Global News

- WHO’s outgoing chief scientist admitted that the WHO should have acknowledged that SARS-CoV-2 could be transmitted through aerosols earlier.
- Measles now an imminent global threat as COVID-19 led to a decline in vaccination coverage and weakened surveillance of the disease, say WHO and US CDC.

Regional News

- China has tightened containment measures across the country as daily cases hit new highs. Residents in Beijing are required to show proof of a negative COVID-19 test, which is not more than 48 hours old, to get into public buildings.
- Japan will extend its domestic travel subsidy program into 2023. Residents need to be triple vaccinated or receive a negative PCR test to benefit from the program. Caseloads continue to rise, driven by the XBB and BQ.1 variants.
- Korea reported more than 50,000 daily cases at the onset of winter. Health authorities vowed to ensure hospitals can accommodate 200,000 patients a day.
- Indonesia has begun administering the second booster dose for elderly people aged 60 and above amid rising COVID-19 cases globally and domestically.

Vaccine News

- Japan has approved its first homemade oral COVID-19 drug for patients with mild symptoms. The drug, Xocova, is effective in speeding up recovery from symptoms and is expected to be available for use by early December.
- Updated COVID-19 boosters offer increased protection against new variants in people who have previously received up to four doses of the older vaccines, a real-world study of more than 360,000 people in the US showed.
## ASEAN+3 and Selected Economies: COVID-19 Cases and Deaths

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.

1/ Values show the 7-day average.

### ASEAN+3 and Selected Economies: Vaccination Coverage Status

(Percent of population)

<table>
<thead>
<tr>
<th>Economy</th>
<th>Total Cases (‘000)</th>
<th>Cases per 1M Population</th>
<th>New Cases</th>
<th>New Cases since 2020</th>
<th>New Cases per 1M Pop.</th>
<th>ΔNew Cases</th>
<th>Δ% New Cases</th>
<th>Total Deaths</th>
<th>New Deaths1</th>
<th>Fatality Rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Global</strong></td>
<td>640,360</td>
<td>491,524</td>
<td>112,836</td>
<td>230,238</td>
<td>7,336</td>
<td>1,037</td>
<td>0.4</td>
<td>4,673,133</td>
<td>1,439</td>
<td>1.0</td>
</tr>
<tr>
<td>ASEAN+3</td>
<td>88,616</td>
<td>164,678</td>
<td>112,836</td>
<td>230,238</td>
<td>7,336</td>
<td>1,037</td>
<td>0.4</td>
<td>4,673,133</td>
<td>1,439</td>
<td>1.0</td>
</tr>
<tr>
<td>Plus-3</td>
<td>53,357</td>
<td>151,411</td>
<td>112,836</td>
<td>230,238</td>
<td>7,336</td>
<td>1,037</td>
<td>0.4</td>
<td>4,673,133</td>
<td>1,439</td>
<td>1.0</td>
</tr>
<tr>
<td>ASEAN</td>
<td>35,299</td>
<td>13,267</td>
<td>112,836</td>
<td>230,238</td>
<td>7,336</td>
<td>1,037</td>
<td>0.4</td>
<td>4,673,133</td>
<td>1,439</td>
<td>1.0</td>
</tr>
</tbody>
</table>

### ASEAN+3 and Selected Economies: Vaccination Coverage Status

Source: Our World in Data via Haver Analytics; and AMRO staff calculations.

Note: Percent of fully vaccinated population shows the number of people who received all doses prescribed by the vaccination protocol (e.g. one dose of a single-dose vaccine, or two doses of a two-dose vaccine). In the event of discrepancy between data from Our World in Data and national authorities, data from national authorities take precedence.
World: New Cases by Region
(7-day average; thousand cases)

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.

ASEAN+3: Daily New Cases by Size of Population
(7-day average; thousand cases)

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.
Note: For ease of comparability, ASEAN+3 economies are grouped by population size.

Selected ASEAN+3: COVID-19 Hospitalizations
(Thousand persons)

Sources: Haver Analytics, sourced from national authorities.

Selected ASEAN+3: Aggregate Non-Residential Mobility
(Percentage change from baseline; 5-day moving average)

Sources: Haver Analytics, sourced from Google COVID-19 Community Mobility reports; and AMRO staff calculations.
Note: Baseline refers to the median value of the corresponding day in the period Jan 3–Feb 6, 2020. “Non-residentials” refer to the aggregated mobility data for places such as groceries and pharmacies, retail and recreation facilities, transit station and workplaces. ASEAN-5 = Indonesia, Malaysia, the Philippines, Thailand, and Singapore. CLMV = Cambodia, Lao PDR, Myanmar, and Vietnam.